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Abstract
Cannabidiol (CBD) is a non-psychoactive derivative from the marijuana plant. Recently, there has been
an explosion of readily available commercial products infused with and marketing CBD contents, and yet
there is a paucity of information regarding the specific effects of CBD on immunity. Our laboratory is
interested in examining the effects of dietary choices on innate immunity, using the immortalized murine
macrophage cell line, RAW 264.7. The objective of this research was twofold. First, to determine if CBD
treatments would exert an observable effect on the murine macrophages when cultured in complete media. Therefore, identical experiments were conducted with two culture conditions, complete media versus
serum-free media, during CBD treatment. Second, to determine the effects of CBD on the proliferation, activation, and inflammatory cytokine production in lipopolysaccharide (LPS)-activated murine macrophages
while also establishing a protocol for treating macrophages with CBD. Macrophage RAW 264.7 cells were
incubated with either control, 0.2, or 20 µM of CBD for 24 hours in serum-free media (SFM) or complete media (CM), followed by a 6 hour, 0.01 or 1.0 µg/ml LPS challenge in SFM. Analyses were done
on total cells counts, cell viability and proliferation, as well as nitric oxide and pro-inflammatory cytokine
interleukin-6 (IL-6) concentrations in cell-conditioned media. We found that macrophages cultured in CM
during CBD treatments had higher percentages of live cells compared to those cultured in SFM with the
exception of SFM and 0.2 µM CBD treatment, in which percent live cells were comparable to CM percent
live counts. Additionally, culturing macrophages in CM, during CBD treatments, resulted in significantly
higher cell viability (MTS assay) compared to macrophages in SFM. There was no significant effect of
CBD or media type on nitric oxide production. At the highest CBD concentration,(20 µM) in SFM, in
addition to the lack of cell growth, proliferation and viability, cells became quiescent and ceased producing
inflammatory cytokine IL-6. Our results suggest that with high 20 µM concentrations of CBD, there is a
marked effect of decreased cell proliferation and pro-inflammatory IL-6 production.

Keywords: CBD · macrophage · inflammation

Introduction

However, twenty years ago, cannabinoids were being
researched by few and was of little interest to many
researchers. Reports from as early as the 1960s have
warned of the potential effects of cannabinoids such
as THC and CBD on human health and decreased
ability to resist infections (Pertwee, 2005). More recently, there has been an increased growth in the
CBD oil market because of factors such as the legalization of cannabis-based products, leading to the
incorporation of its oil into our supplements, food,
and body care products (MarketWatch, 2019). In the
past THC has received considerably more attention
than CBD, the recent rise in commercialization and
more relaxed regulations have made CBD a topic of
interest in healthcare and commercial products alike.
Since, CBD’s specific effects on the body have only
recently started being explored the need for laboratory and clinical research on its specific effects has
risen.

Cannabidiol Molecule
The marijuana plant, Cannabis sativa, has a host of
derived molecules and cannabinoids that are of research interest for their various functions and potential health effects. Cannabidiol (CBD) is one
such molecule (Figure 1), and is not only the most
abundant nonpsychotropic plant cannabinoid, but
has been touted as an natural remedy for a variety of health issues such as chronic pain, insomnia and anxiety. Yet another derivative is ∆9 tetrahydrocannabinol (THC) which is the major psychoactive ingredient and has also been implicated in
various immunomodulatory effects.
Usage of the marijuana plant by people for its
fibers, food, rituals, or believed health benefits dates
back to pre-Neolithic times (Clarke & Merlin, 2013).
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of pathogens and foreign organisms as well as dealing with the internal risk factors such as autoimmune
diseases. It is recognized that the age-associated decline in immunologic vigor directly or indirectly contributes to increased susceptibility to infectious diseases, meaning avoiding decreasing the inflammatory
response to a drastic extent may prove deadly (Wu et
al., 2008). Determining how inflammatory function
is affected by various factors, such as CBD and CBD
concentration, are important to understand in order
to decide how it would be used commercially and in
the healthcare setting.

Figure 1: Cannabidiol Molecule

Inflammation
Effects of Cannabidiol on Inflammation

Macrophages are immune cells that scavenge for invading pathogens and help link innate and adaptive immunity by stimulating lymphocytes and other
adaptive immune cells to respond to foreign invaders. Macrophages help determine the extent, as
well as the type, of immune response that will be
mounted against an invading pathogen. Chemokines
and cytokines produced by macrophages help recruit
and activate other immune cells to the area where
the pathogen was encountered. One of the important cytokines produced by macrophages is the proinflammatory cytokine interleukin-6 (IL-6) (Janeway
et al., 2001). Interleukin-6 is multi-functional, acting
as a signaling molecule to hematopoietic stem cells,
hepatocytes and immune B cells (Matsuda & Kishimoto,1998). The importance of IL-6 in many physiological functions makes it the perfect candidate for
the initial testing of the immune response to CBD.
Chronic inflammation has been implicated as a
cancer causing pathway through tissue destruction
and scarring, and reshaping of the tissue architecture
as well as contributing to changes in gene expression
that may result in tumorigenesis (Hunter, 2012). Understanding how inflammation can be mediated and
suppressed in some cases can allow us to curb the onset or even progression of these inflammation-related
diseases.
Suppression of the inflammatory response may provide relief for those suffering chronic pain but may
be dangerous for lowering the defenses against bacterial and other infections. Normal immune functions is critical for surviving in an environment full

With the potential benefits of CBD, there have been
studies done on various cell lines and mouse models
to test its immunomodulating effects. The proposed
immunomodulating effects of CBD are thought to be
related to its strong immunosuppressive effects due
to its ability to suppress the proliferation of lymphocytes and production of inflammatory proteins in
mice treated with high doses (Kaplan et al., 2008).
The way in which the CBD molecule is able to
have an immunomodulating effect on cells within
an organism is through the CB1 and CB2 receptors. It has been discovered that the CB2 receptor is mainly expressed in immune cells including
monocytes, the precursors to macrophages. Additionally, is has been found that in mouse monocytes
that a predominance of CB2 receptors resulted in a
stronger anti-inflammatory response, such as an inhibition of chemotactic movement in response to monocyte chemo-attractant protein 1 when stimulated by
cannabinoids (Han et al., 2009). Essentially, CBD
acts as an inverse antagonist at the CB2 receptors
meaning that it is able to inhibit the migration of
immune cells therefore exerting an anti-inflammatory
effect (Watt & Karl, 2017).
With the increase in legalization and interest in
the CBD molecule, it has been extensively studied
in the last decade. There is a current trend in the
medical industry to include CBD as a possible treatment for many ailments, from neurologic disorders
like epilepsy and seizures to inflammatory and autoimmune diseases. There is current research on the
3

beneficial effects of CBD in animal models of multiple sclerosis, rheumatoid arthritis, diabetes, and
Alzheimer’s disease, among others (Kozela et al.,
2011; Malfait et al., 2000; Weiss et al., 2008; Watt
and Karl, 2017).
The benefit of decreased anti-inflammatory proteins released from macrophages has also been tested
in diabetic mouse models. In young non-obese
diabetes-prone mice administered with CBD, symptoms of initial or latent diabetes stages were ameliorated and levels of pro-inflammatory cytokine IL-12
produced by splenocytes were significantly reduced
(Weiss et. al, 2008). Although there is plenty of scientific literature using animal or cell-based immunological models for CBD research, the investigations
into the effects of CBD therapy on the immunity of
human subjects is quite limited. Past studies with
human subjects have primarily focused on healthy
individuals, rather than those suffering from chronic
disease, and the use of cannabis on circulating proinflammatory cytokine concentrations in the blood
(National Academies of Sciences, Engineering, and
Medicine, 2017). With the continued research into
the effects of CBD in immunity and positive therapeutic results, future directions may include more
human based studies.

was to test the effects of CBD on the proliferation, activation, and inflammatory cytokine production in lipopolysaccharide (LPS)-activated murine
macrophages.

Experimental Design
To test our first objective of creating a protocol to
determine if CBD would have a an observed effect
in complete media we created two distinct culture
conditions using complete media or serum-free media
for the duration of the CBD treatments. Serum-free
media lacks bovine serum albumin compared to complete media. The activation of macrophages via LPS
was still done in SFM as the macrophage activation
efficacy of LPS is diminished in complete media.
In addition to the culturing of macrophages within
two different media types, the quality and quantity of
cells were analyzed as well as important inflammatory
markers, nitric oxide and pro-inflammatory cytokine
IL-6, were quantified from the conditioned media after LPS-stimulation. This was necessary in order to
address our secondary objective: measuring the concentration of the pro-inflammatory molecule IL-6 to
observe the potential immunomodulating effects of
varying CBD concentrations on mouse macrophage
immune cells.

Research Objectives

Materials and Methods

Culture Conditions The primary objective of
this research was to determine the appropriate
methodology and protocol for treating murine
macrophages with physiological concentrations of
CBD in vitro. Since we did not know if CBD would
only be taken up by serum-starved cells we designed
the experiments to test complete versus serum-free
media.

Materials
Murine macrophages (RAW 264.7) were purchased
from ATCC (Manassass, VA). Dulbecco’s modified
Eagle’s medium (DMEM), phosphate buffered saline
(PBS), fetal bovine serum (FBS), and penicillinstreptomycin were purchased from Fisher Scientific
(Pittsburg, PA). The cannabidiol molecule was obtained from Cayman (item: 90081) suspended in
methanol. The methanol was replaced with ethanol
by drying out the methanol with N2 gas and reconstituting the CBD in 2 ml of pure ethanol. Lipopolysaccharide for macrophage stimulation was obtained
from E. coli. The interleukin IL-6 enzyme-linked immunosorbent assays (ELISA) were purchased from

Effects on Inflammation If CBD can suppress
inflammatory molecule production in murine models then it makes sense to research its immunomodulating ability in mouse macrophages. The important question we ask is: do physiological doses
of CBD affect inflammatory parameters in mouse
macrophages? Therefore the secondary purpose
4

R&D systems (Minneapolis, MN). Griess assay’s for Cytotoxicity Analysis
nitric oxide (NO) quantification and MTS assay for
cell proliferation quantification were obtained from During collection of cell conditioned media, 1 ml was
retained in the wells for cell scraping and cell counts.
Promega (Madison, Wisconsin).
From each well 100 µl of cells and 100 µl of trypan blue were mixed. From this mixture, 10µl were
applied to hemocytometer slides and inserted into
Cell Culture and Treatment
the CountessTM II FL cell counter (Fisher Scientific,
RAW 264.7 murine macrophages were cultured in Pittsburgh, PA), to determine total concentration of
Gibco DMEM with 10% FBS and 1% penicillin- cells, percent live, and dead cells.
streptomycin in polystyrene 6-well plates. Cells were
incubated at 37 ◦ C in a humidified environment of
95% O2 5% CO2 . Complete and serum-free media
were prepared the same with antibiotics for incubation of macrophages, with the exception of SFM
which lacked bovine serum albumin compared to
complete media. Medium was changed every two
days and the cells were not grown beyond 80% confluency during expansion. Experiments were performed
with cells not surpassing 15 passages. For CBD treatments, cells were grown until 80-90% confluence followed by a 24 hour CBD treatment, either an ethanol
control, 0.2 µg/ml, or 20 µg/ml of CBD. Following
CBD treatment, supernatant was removed, cells were
washed twice with 1X PBS and serum-free media was
added along with 0.01 or 0.1 µg/ml of LPS. After a
6 hr incubation, cell-conditioned media was collected
and stored in -80◦ C until NO, and IL-6 analysis. Cell
counts were performed immediately following the 6
hr LPS challenge. Experiments were conducted five
times.

Nitric Oxide (NO) Concentration
Analysis of NO concentration in samples was done using a Griess Reagent kit, with samples tested in triplicate. The standard curve was used to extrapolate
the concentrations of NO from the samples. Measurements were taken by Epoch spectrophotometer
at 548 nm.

IL-6 Concentration
Analysis of IL-6 in samples was done using enzymelinked immunosorbent assay (ELISA). Plates were
coated with capture antibody 24 hr before use with
samples tested in triplicate. The standard curve was
used to extrapolate the concentrations of IL-6 from
the samples.

Statistics
Results are expressed as a mean ± SEM. Nitric oxide and percent live cells data were normalized using a log base 10 transformation, and ArcSin square
root, respectively. Concentrations of IL-6 and NO in
cell culture medium and were analyzed using Multiway split-plot ANOVA. When treatment effects were
detected (p < 0.05), means were separated using
Tukey’s HSD. For the IL-6, NO, percent live, MTS,
and total cells, the sources of variation included
experiment, treatment, experiment∗treatment, and
well(experiment∗treatment), with the experiment
considered a random variable. All statistical analyses were performed using JMP Pro 14 while figures
and images were created via Tableau.

Cell Proliferation Analysis
An MTS assay was run concurrently with each experiment. Cells were seeded in a 96-well plate at an
initial concentration of 0.01 ∗ 106 cells per well. Once
a confluency of 80% was reached, macrophages were
treated with appropriate CBD concentrations of either control, 0.2 µg/ml, or 20 µg/ml for 24 hrs. Subsequently, after 6 hr LPS stimulation, CellTiter 96 R
AQueous One Solution Reagent was added directly to
wells and incubated at 37 ◦ C. Measurements were
taken at 1 and 2 hrs by Epoch spectrophotometer at
490 nm.
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Figure 2: Total cells measured by cell count of RAW 264.7 cells treated with 1.0 µg/ml LPS after CBD preincubation (a) Average total number of cells counted in both serum-free and complete media and separated by CBD
treatment (p=0.03). (b) Average total number of cells counted separated by media type (p =0.003). Treatments were
compared using a split-plot ANOVA, followed by post-hoc Tukey-Kramer HSD. Significant differences are represented
with different letters (p < 0.05). Bars represent the mean ± pooled S.E.M. (n = 5).

Results

production (Figure 6) in both complete media and
serum-free media.

In our study, we evaluated the importance of complete versus serum-free media in examining the effects
of CBD on various cytokines and cellular functions
in in vitro LPS-stimulated murine macrophage RAW
cells. In order to determine if maintaining the murine
macrophages in serum-free media during CBD incubation would have an effect on cell viability RAW
264.7 cells were incubated with either control, 0.2, or
20 µM of CBD for 24 hour in serum-free media (SFM)
or complete media (CM), followed by a 6 hour, 0.01
or 1.0 µg/ml LPS challenge in SFM. These results
suggest that concentrations of 0.2 and 20 µM CBD
have significant effects on murine macrophage proliferation (Figure 3), viability (Figure 2 & 4), and IL-6

Cell Viability
Amongst the CBD treatments, for both media types,
total cells counts were significantly affected (p =
0.033) by the 0.2 µM CBD treatment averaging
higher in cell counts than 20 µM CBD treatments
(12465375 ± 2784496, 4944137 ± 2784496)(Figure 2a).
However, both 0.2 and 20 µM CBD treatments were
not significantly different than the control containing
no CBD.
When comparing total cells by media type
treatment, cells grown in complete media during CBD treatment incubation resulted in a sig6

Figure 3: Cell proliferation measured by MTS of RAW 264.7 cells activated with LPS after CBD 24 hr preincubation (a) Average cell proliferation measured in both media types for different CBD treatments (p < 0.0001)
(b) Calculated average cell proliferation separated by media type (p=0.0008). Treatments were compared using a
split-plot ANOVA, followed by post-hoc Tukey-Kramer HSD. Significant differences are represented with different
letters (p < 0.05). Bars represent the mean ± pooled S.E.M. (n = 4).

nificantly higher average cell count (12498542 ±
2556384, 5592883 ± 2556384; p = 0.003) than its
serum-free treatment counter part (Figure 2b). CBD
concentrations had similar effects on cell viability regardless of media type on cell viability (CM control
13221750 ± 3377627, 0.2 µM 14805750 ± 3377627, 20
µM 13221750 ± 3377627 and SFM control 6233500 ±
3377627, 0.2 µM 10125000±3377627, 20 µM 420150±
3377627 total cells; p = 0.73).

(0.2±0.06, 0.69±0.06, 0.65±0.06; p < 0.0001) (Figure
3a).
When comparing the two media types, serum-free
media had an average proliferation of cells much
lower than cells cultured in complete media during
CBD treatment (0.38 ± 0.53 and 0.65 ± 0.53; p =
0.0008)(Figure 3b). There was no significant effect
of a media type and CBD treatment interaction on
cell proliferation (p = 0.09).

Cell Proliferation

Cytotoxicity Analysis

Cell proliferation was determined via MTS proliferation assay. Murine macrophages in both media types
treated with 20 µM CBD on average had significantly
lower proliferation than control or 0.2 µM treatments

Cytotoxicity of the CBD treatments and media
types was tested by using the Trypan blue exclusion method to measure the percentage of murine
macrophage live cells (Figure 4). There was an in7

Figure 4: Percent live RAW 264.7 cells after 6 hr LPS
challenge with CBD 24 hr pre-incubation. Average percentage of live cells divided by different media types and
CBD treatments. Complete media p = 0.92 while serumfree
√ media p = 0.002. Data was normalized using a
arcsin transformation and treatments were compared
using a split-plot ANOVA, followed by post-hoc TukeyKramer HSD. Significant differences are represented with
different letters (p < 0.05). Bars represent the mean ±
individual S.E.M. (n= 5).

Figure 5: Nitric oxide production by RAW 264.7
cells treated 1.0 µg/ml with LPS after CBD 24 hr preincubation. Calculated average of nitric oxide production
for both complete and serum-free media and separated by
CBD concentration (n= 4). Data was normalized using a
log transformation and treatments were compared using
a split-plot ANOVA. Bars represent the mean ± pooled
S.E.M (p < 0.05).

teraction effect between media type and CBD treatment (p = 0.0053) which was further analyzed by
media type to reveal that macrophages cultured in
complete media had no difference in percent live cells
across all CBD treatments (p = 0.92).
Meanwhile, cells grown in serum-free media had
significantly varied percent live counts based on CBD
treatment with the 0.2 µM CBD treatment resulting in much higher percent live cells than the control
and 20 µM CBD treatment (p = 0.0024). Overall, SFM+20 µM CBD treatment resulted in the
lowest percent live count. Macrophages cultured
in complete media had higher percentages of live
cells compared to those cultured in serum-free media (53.2±5.6% vs 35.2±5.6% live; p < 0.0001).
There was no significant effect of LPS concentration (0.1 versus 1.0 µg/ml) for stimulation (p = 0.45)

on test effects of CBD or media type.

Nitric Oxide (NO) Concentration
Nitric oxide levels were quantified in order to examine the activation level of the macrophages (Figure
5). There was no significant difference in NO production from the RAW macrophages between CBD
treatment concentrations or media type (p = 0.52).
On average, amongst the three CBD treatment concentrations, cell production of nitric oxide averaged
0.55 ± 0.52.
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Figure 6: IL-6 concentrations in conditioned media produced by RAW 264.7 cells treated with 1.0 µg/ml LPS
after CBD pre-incubation (a) Average IL-6 produced calculated from both media types and separated by CBD
concentration (p = 0.038). (b) Average IL-6 produced with bars separated by CBD concentration within different
media types (p = 0.059).Treatments were compared using a split-plot ANOVA, followed by post-hoc Tukey-Kramer
HSD. Significant differences are represented with different letters (p < 0.05). Bars represent the mean ± pooled
S.E.M (n= 2).

IL-6 Concentration

CBD treatments. Overall, there was no significant effect of media type on cell IL-6 production (p = 0.09).

Only experiments that stimulated macrophages using 1.0 µg/ml of LPS after CBD treatment were analyzed for IL-6 production levels (n=2). On average,
between the two media types, the 20 µM CBD treatment had significantly decreased cellular IL-6 production compared to the control (43.7 ± 41.43 and
206.8 ± 41.7pg/106 , p = 0.038, Figure 6a).
When CBD treatment effects were separated based
on media type, there was a trend that indicated
that in serum-free media, 20 µM CBD treatment resulted in a complete elimination of IL-6 production
compared to control and 0.2 µM CBD treatments
(7.1∗10−14 ±57.4, 302.3±57.4, 239.6±57.4pg/106 ; p =
0.059, Figure 6b). Meanwhile, in complete-media and
CBD treated cells, there was no difference between
the IL-6 concentrations produced across all of the

Discussion
Methodology
While drawing on past research into CBD’s effects
on other cell lines and ailments, our project aimed
to establish a protocol for the culturing and treatment of murine macrophages with CBD while observing the effects of varying concentrations of CBD
on cell viability, proliferation, cytotoxicity, NO and
IL-6 production. This methodology will hopefully enable further research into CBD’s effects on murine
macrophages while also providing a useful tool for
analysis of additional specific cytokines that affect
9

inflammation.

CBD effects

Based on the results of this study we would proceed
with the use of complete media for future experiments
testing the effects of CBD on murine macrophages.
In our previous work with fatty acids and murine
macrophages we used serum-free media as a means
of ensuring the delivery of our fatty acid treatment
into the cells. To determine if this was necessary
for CBD we chose to duplicate the CBD treatments
into two media type conditions, serum-free and complete media. There was an observed effect of CBD on
macrophage function compared to the control in experiments with the complete media condition. Therefore it can be determined that cannabidiol has an
effect on macrophages with or without complete media. It is still necessary to utilize serum-free media
when conducting the macrophage LPS challenge post
CBD treatment as LPS is deactivated when used with
complete media.

These results suggest that in general, concentrations
of 0.2 and 20 µM CBD have no detrimental effects
on murine macrophage viability. We are unable to
conclude on the result of the nitric oxide assay as
there were no significant effects due to large variability of measured nitric oxide concentrations for each
treatment and media type.
We are able to see that for percent live cells in
complete media, there is no evident cytotoxic effect
of the higher concentration of 20 µM CBD. With the
serum-free media there is significantly lower percent
live cells but this is also in combination with a general lack of total cells and significantly lower proliferation levels (MTS assay) signifying a lack of growth
of cells and cell death. It is known that cannabinoid
receptors modulate several signalling pathways that
are directly involved in the control of cell proliferation and survival. For example, various cannabinoids
have been found to exert an antiproliferative action
on a wide spectrum of cultured tumor cells (Pertwee,
2005). With this lack of cells in the SFM+20µM CBD
treatment, it is understandable why IL-6 production
is decreased to almost zero. Therefore, the 20 µM
CBD concentration is not more cytotoxic than 0.2
µM CBD concentrations but, for the higher concentration there is a decrease in proliferation as well as
a decrease in the inflammatory cytokine IL-6. These
effects can be translated to positive results for certain
ailments, for it has been observed that in pre-diabetic
mice treated with CBD, there was a significant decrease of IL-6 in mouse plasma, as well as a decrease
in risk of diabetes development in adulthood (Weiss
et al., 2009).
When comparing total cell with MTS proliferation
data, there is a pattern in the effect of CBD concentration on the average values, with the exception of
a slight increase in 0.2 µM CBD treated total cells
counts compared to the MTS data which has lower
proliferation for the same treatment. At the high 20
µM CBD concentration, cells became quiescent and
stopped producing inflammatory cytokine IL-6 in addition to the lack of cell growth, proliferation and
viability. In encephalitogenic MOG-specific T cells
treated with CBD, there was an antiproliferatory ef-

Using complete media is favorable as on average,
experiments result in higher total cells, percent live
counts, and proliferation than those with serum-free
media. Cell proliferation was measured to have the
same effects for the CBD treatments regardless of
media-type, allowing us to choose the media type
based on the total cell and percent live differences.
However, within our IL-6 results, differences between
CBD concentrations are more easily observed in the
SFM. In previous research using complete media and
CBD pre-treatments on murine macrophages, Rajan
et al.(2016) performed 2 hour 5 µM CBD treatments
followed by 24 hr LPS stimulation. A longer LPS
stimulation may be necessary for future complete media CBD treatment experiments to see more observable differences between cytokine production levels.
Based on our results of this study it can be expected
that future CBD experiments using complete media
should result in similar percent live values across different CBD treatments in the 0.2 to 20 µM concentration range. Additionally, cells grown in serum-free
media during the CBD pre-treatment period did not
grow as much as those grown in complete media during this period which proves difficult to measure cytokine levels when there are minimal cells producing
them.
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fect in antigen-induced cell proliferation (Kozela et
al., 2011). These RAW macrophages were also stimulated via LPS antigens after CBD treatment and display a similar inhibitory effect on proliferation, especially with increased concentrations of 20 µM CBD.
It may be possible to increase the effectiveness of
the CBD molecule by altering its binding ability to
the CB1 and CB2 receptors. An experiment was conducted in which four derivatives of CBD were tested
for their ability to modulate NO, TNF-α, reactive
oxygen intermediates and their binding to CB1. Two
of the derivatives showed an increased suppressive effect of these inflammatory markers which may be a
path for developing therapeutic agents to modulate
nitric oxide and TNF-α production (Ben-Shabbat et
al., 2006).

found mainly on immune cells has a role in modulating cytokine release and is a target of interest for us
(Pertwee, 2005). Finally, we have raised the question:
do physiological doses of CBD affect inflammatory
parameters in mouse macrophages and adipocytes?
We will work to observe inflammatory molecule production by adipocytes and macrophages, separately,
as well as co-incubated after treatment with CBD.

Conclusion

[2] Robert C. Clarke; Mark D. Merlin (1 September
2013). Cannabis: Evolution and Ethnobotany.
Univ of California Press.

References
[1] Ben-Shabat S, Hanus L, Katzavian G, Gallily R,
2006. New Cannabidiol Derivatives: Synthesis,
Binding to Cannabinoid Receptor, and Evaluation of their Antiinflammatory Activity. J. Med.
Chem. 49:1113.

The study of the effects of the cannabidiol molecule
are a quickly developing field and the need for un- [3] Fain J., 2010. Release of Inflammatory Mediators
derstanding how to culture cells with this molecule is
by Human Adipose Tissue Is Enhanced in Obesity
the most basic of information needed to proceed. We
and Primarily by the Nonfat Cells: A Review.
have been able to determine a methodology for the
Mediat. Infl. 1-20.
culture and treatment of murine macrophages with
different concentrations of CBD. The establishment [4] Ki Hoon Han, Sunny Lim, Jewon Ryu, CheolWhan Lee, Yuna Kim, Ju-Hee Kang, Soon-Suk
of this methodology of using complete media has proKang, Yeong Ki Ahn, Chan-Sik Park, Jae Joong
vided us with the groundwork for our initial findings
Kim, 2009. CB1 and CB2 cannabinoid receptors
into the variable effects of different CBD concentradifferentially regulate the production of reactive
tions on the functions and cytokine production of
oxygen species by macrophages, Cardiovascular
murine macrophages.
Research. 84(3): 378–386.

Future Directions

[5] Hunter, P., 2012. The inflammation theory of disease. EMBO reports. 11:968-970.

With this exploration we have identified the effects
of CBD on a few specific cellular markers, and the [6] Janeway CA Jr, Travers P, Walport M, et
pro-inflammatory cytokine IL-6. Nevertheless, there
al. Immunobiology:
The Immune System
are many other cytokines that macrophages produced
in Health and Disease. 5th edition. New
that impact inflammatory as well as other important
York: Garland Science; 2001. Principles of
biological pathways. By using the protocol we esinnate and adaptive immunity. Available from:
tablished for culturing macrophages with CBD we
https://www.ncbi.nlm.nih.gov/books/NBK27090/
can now examine these other cytokines. One such
macrophage product that is of interest to us is TNF- [7] Kaplan, Barbara L F et al. “The profile of imα because suppression of it inhibits inflammatory
mune modulation by cannabidiol (CBD) involves
damage. Additionally, the cannabinoid receptor CB2
deregulation of nuclear factor of activated T cells
11

(NFAT).” Biochemical pharmacology vol. 76,6
(2008): 726-37.
[8] Kozela E, Lev N, Kaushansky N, Eilam R, Rimmerman N, Levy R, Ben-Nun A, Juknat A, Vogel
Z. 2011. Cannabidiol inhibits pathogenic T cells,
decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6
mice. Br J Pharmacol. 163:1507.
[9] Malfait AM, Gallily R, Sumariwalla PF, Malik
AS, Andreakos E, Mechoulam R, Feldmann M.
2000. The non-psychoactive cannabis constituent
cannabidiol is an oral anti-arthritic therapeutic
in murine collagen-induced arthritis. Proc Natl
Acad Sci U S A. 97:9561.
[10] Matsuda T., Kishimoto T., 1998. Interleukin
6.Encyclopedia of Immunology (Second Edition).
[11] National Academies of Sciences, Engineering,
and Medicine. 2017. The health effects of cannabis
and cannabinoids: The current state of evidence and recommendations for research. Washington, DC: The National Academies Press. doi:
10.17226/24625.
[12] Pertwee R, 2005. Cannabinoids. Springer.
[13] Rajan T et al., 2016. Anti-inflammatory and antioxidant effects of a combination of cannabidiol
and moringin in LPS-stimulated macrophages. Fitoter 112:104.
[14] Watt G, Karl T. 2017. In vivo Evidence for
Therapeutic Properties of Cannabidiol (CBD) for
Alzheimer’s Disease. Front Pharmacol. 8:20.
[15] Weiss L, Zeira M, Reich S, Slavin S, Raz I, Mechoulam R, Gallily R. 2008. Cannabidiol arrests
onset of autoimmune diabetes in NOD mice. Neuropharmacology. 54:244.
[16] Wu, Dayong, and Simin Nikbin Meydani. “Ageassociated changes in immune and inflammatory
responses: impact of vitamin E intervention.”
Journal of leukocyte biology vol. 84,4 (2008): 90014.

12

